Janux Therapeutics, Inc. (JANX)
- Previous Close
47.10 - Open
47.08 - Bid 46.92 x 200
- Ask 47.29 x 100
- Day's Range
46.61 - 48.23 - 52 Week Range
5.65 - 58.69 - Volume
389,157 - Avg. Volume
947,111 - Market Cap (intraday)
2.433B - Beta (5Y Monthly) 4.18
- PE Ratio (TTM)
-- - EPS (TTM)
-1.32 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
58.29
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
www.januxrx.comRecent News: JANX
Performance Overview: JANX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: JANX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: JANX
Valuation Measures
Market Cap
2.43B
Enterprise Value
2.11B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
256.48
Price/Book (mrq)
7.07
Enterprise Value/Revenue
261.50
Enterprise Value/EBITDA
-29.76
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.25%
Return on Equity (ttm)
-17.53%
Revenue (ttm)
8.08M
Net Income Avi to Common (ttm)
-58.29M
Diluted EPS (ttm)
-1.32
Balance Sheet and Cash Flow
Total Cash (mrq)
344.03M
Total Debt/Equity (mrq)
7.13%
Levered Free Cash Flow (ttm)
-29.52M